Evogene Partners with Unravel Biosciences to Innovate Therapy for Demyelinating Disorders
Evogene Ltd. (Nasdaq: EVGN), a leader in computational chemistry, has announced a groundbreaking collaboration with Unravel Biosciences, Inc. This partnership aims to advance the discovery of a pioneering small-molecule therapy designed to restore myelin and reverse neurological damage associated with demyelinating diseases, including Multiple Sclerosis (MS).
The Need for Remyelination Therapies
Demyelinating diseases are a major public health issue, impacting hundreds of millions globally. Among these, Multiple Sclerosis affects approximately 3 million people each year. Current treatment options primarily focus on slowing disease progression rather than repairing existing neurological damage.
The absence of effective therapies that can reverse myelin loss signifies a critical gap in treating patients with demyelinating disorders. The collaboration between Evogene and Unravel aims to address this unmet need through innovative approaches to drug development.
Innovative Collaboration Approach
This collaboration will utilize Evogene's advanced ChemPass AI technology, combined with Unravel's AI-driven BioNAV™ predictive biology platform, to identify and optimize new therapeutic candidates. This synergistic approach promises to unveil critical biological insights for successful remyelination strategies.
Key elements of the collaboration include:
- Design and validation of brain-penetrant inhibitors targeting novel demyelination pathways.
- Function-first discovery to translate biological insights into effective drug targets.
- Optimization of drug candidates through generative AI methodologies.
Expert Insights on the Collaboration
Dr. Richard Novak, CEO of Unravel Biosciences, expressed enthusiasm about the partnership, stating, "We are thrilled to partner with Evogene to design optimized new therapeutic candidates to promote remyelination for MS and other neurodegenerative disorders."
Ofer Haviv, President and CEO of Evogene, added, "This collaboration integrates cutting-edge scientific innovation with urgent clinical needs. Our ChemPass AI engine is uniquely equipped to design novel small molecules to efficiently target the demyelination process."
About Evogene Ltd. and Unravel Biosciences
Evogene Ltd. (Nasdaq/TASE: EVGN) is a pioneering company focused on computational chemistry for pharmaceuticals and agriculture. Its ChemPass AI engine significantly improves the design of small molecules, enhancing success rates while reducing development times.
Unravel Biosciences is a clinical-stage therapeutics firm that leverages AI-driven systems biology and rapid clinical validation. Their innovative BioNAV™ platform allows for the creation of Living Molecular Twins™, enhancing target and drug discovery for complex diseases.
Looking Ahead
With this collaboration, both Evogene and Unravel aim to pave the way for transformative treatments for patients suffering from demyelinating disorders. The integration of advanced technological platforms and deep biological insights may finally provide the solution needed for successful remyelination.
For more information, visit Evogene's official site and Unravel Biosciences' site.